Share |
Organization DBA --
Former Names Sidney Farber Cancer Center (1983)
Children's Cancer Research Foundation (1974)
Organization received a competitive grant from the Boston Foundation in the past five years No

Summary

Mission StatementMORE »

Founded in 1947, Dana-Farber Cancer Institute’s mission is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations and disseminates innovative patient therapies and scientific discoveries in Boston, across the United States and throughout the world.

Mission Statement

Founded in 1947, Dana-Farber Cancer Institute’s mission is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations and disseminates innovative patient therapies and scientific discoveries in Boston, across the United States and throughout the world.

FinancialsMORE »

Fiscal Year Oct 01, 2011 to Sept 30, 2012
Projected Income $1,000,863,483.00
Projected Expense $994,919,900.00

ProgramsMORE »

  • A. Patient Care
  • B. Research
  • C. Training
  • D. Community Based Programs

Revenue vs. Expense ($000s)

Expense Breakdown 2013 (%)

Expense Breakdown 2012 (%)

Expense Breakdown 2011 (%)

For more details regarding the organization's financial information, select the financial tab and review available comments.


Overview

Mission Statement

Founded in 1947, Dana-Farber Cancer Institute’s mission is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations and disseminates innovative patient therapies and scientific discoveries in Boston, across the United States and throughout the world.

Background Statement

In 1947, Sidney Farber, MD, founded the Children's Cancer Research Foundation, dedicated to providing compassionate, state-of-the-art treatment to children with cancer while developing cancer preventatives, treatments and cures of the future. The foundation officially expanded its programs to include patients of all ages in 1969, and in 1974 became known as the Sidney Farber Cancer Center. The long-term support of the Charles A. Dana Foundation was acknowledged by incorporating the Institute under its present name in 1983.

Today, Dana-Farber employs over 4,000 people supporting more than 350,000 patient visits a year and participates in nearly 700 clinical trials. Its international reputation for blending research and clinical excellence uniquely positions the Institute to develop and test the next generation of cancer therapies in both the laboratory and the clinic.
 
Dana-Farber is a principal teaching affiliate of Harvard Medical School, a federally designated Center for AIDS Research and the founding member of the Dana-Farber/Harvard Cancer Center, a federally designated comprehensive cancer center comprised of seven Harvard-affiliated hospitals and more than 900 investigators who have made astounding discoveries and continue to work tirelessly to translate those discoveries into better approaches for diagnosis and treatment.
 
Providing advanced training in cancer treatment and research for an international faculty, the Institute conducts community-based programs in cancer prevention, detection, and control throughout New England, and maintains joint programs with other Boston institutions affiliated with Harvard Medical School and the Partners Health Care System, including Brigham and Women's Hospital, Boston Children's Hospital and Massachusetts General Hospital.
 
Dana-Farber is supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the generous support of numerous foundations and individuals who contribute to the Institute's research and clinical programs or to The Jimmy Fund, the principal charity of the Institute, named for one of its child patients.

Impact Statement

Ranked New England’s best and the country’s 5th best cancer hospital by U.S. News & World Report, Dana-Farber’s equal commitment to research & patient care is unique among cancer institutions. This 50-50 balance results in extraordinary partnerships between laboratory scientists and clinicians to ensure that each patient’s medical, psychological, family and spiritual needs are addressed throughout their entire cancer journey. Regardless of age, teams of multi-disciplinary experts focusing on the same type of cancer collaborate to offer novel therapies to patients and access to innovative clinical trials. Our network of support services is comprehensive and specialized to address unique patient needs at every stage of treatment and life. Last year, the Institute treated more than 47,000 adult patients through 350,000 visits in 13 specialized centers; and the Jimmy Fund Clinic treated more than 2,400 patients through nearly 15,000 visits.

Dana-Farber’s history of groundbreaking discoveries traces back to its founder, Dr. Sidney Farber, the “father of chemotherapy”, and first physician to attain remissions of acute lymphoblastic leukemia, the most common childhood cancer. In the 1970s, our scientists pioneered combination chemotherapy, using multiple drugs to treat cancer more effectively. In the 1980s, the Institute was the first to implement autologous bone marrow transplantation, a life-saving procedure that reduces the risk of transplant rejection due to imperfect matches. Also in the 1980s, Dana-Farber scientists identified the human T-cell receptor, a key mechanism that led to vastly increased understanding of HIV/AIDS. In 2011, we launched Profile, one of the most extensive genotyping projects in cancer research nationally, allowing the Dana-Farber/Brigham and Women’s Cancer Center to test all consenting patients’ tumor tissue for nearly 500 cancer-causing mutations in 41 cancer genes and generate data to better understand the causes, treatments and prevention of cancer.

Needs Statement

Dana-Farber is proud to be at the forefront of dramatic advances in cancer research and treatment and remains committed to conquering all forms of cancer. Our successes to date would not have been possible without the partnership of generous donors. While we have made great strides, there is still much work to be done to develop better treatments to improve outcomes for all who suffer from this insidious disease. Unrestricted funds are enormously important because they can be directed where and when they are needed most, helping to ensure that we have the necessary flexibility to sustain novel research and seize every opportunity in patient care, without financial restraints imposed by economic downturns and a challenging federal funding climate. Such fundsallowus to be nimble in our tireless pursuit to better understand,treat and ultimately eradicate cancer. Among many other priorities, your support will bolster the Institute’s ability to address patients’ and families’ medical and psychosocial needs; provide seed funds for the most innovative early stage investigations not yet eligible for federal funding; educate the wider community about the importance of cancer prevention and screening; and support training programs for the next generation of scientists in the fight against cancer.


CEO Statement

--

Board Chair Statement

--

Geographic Area Served

GREATER BOSTON REGION, MA
NORTHEAST REGION, MA

Dana-Farber Cancer Institute has partnerships with the following adult outpatient centers and considers these satellite locations:

  •  Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) at Faulkner Hospital in Jamaica Plain, Massachusetts
  • DF/BWCC at Milford Regional Medical Center in Milford, Massachusetts
  • Dana-Farber/New Hampshire Oncology-Hematology in Londonderry, New Hampshire
  • DF/BWCC in clinical affiliation with South Shore Hospital in Weymouth, Massachusetts

 

Organization Categories

  1. Health Care - Hospitals
  2. Health Care - Hospitals
  3. Health Care - Fund Raising & Fund Distribution

Independent research has been conducted on this organization's theory of change or on the effectiveness of this organization's program(s)

Under Development

Programs

A. Patient Care

Dana-Farber provides outpatient care to adult patients in 13 specialized centers and partners with Brigham and Women’s Hospital to provide inpatient care. Pediatric patients receive outpatient care at our Jimmy Fund Clinic and inpatient care is provided by Children's Hospital Boston.
Budget  n/a
Category  Health Care, General/Other Patient Care/Health Care Delivery
Population Served Adults
Program Short-Term Success 

The Yawkey Center for Cancer Care, which opened in February 2011, adds 275,000 square feet of clinical and support space and is designed to accommodate more than 100 exam rooms, more than 150 infusion spaces, and 20 consultation rooms. This clinical care facilitywas designed with advice from patients, families, and staff to advance clinical care, optimize patient safety, enhance the patient experience, and provide an environment that fosters healing. Programs and resources such as our pioneering use of ERSA-C (Electronic Self-Report Assessment-Cancer), a first-of-its-kind computer program that helps patients track their symptoms and allow doctors to monitor them between visits, and our pilot of a real-time locating system to identify the locations of patients and staff and reduce wait times ensure that all of our patients’ physical, emotional, and spiritual needs are met during and ease the burden of cancer treatment.

Program Long-Term Success 
U.S. News & World Report’s Best Hospitals guide ranked Dana-Farber/Brigham and Women's Cancer Center the top cancer center in New England, for the 12th year in a row, and fifth overall in the country. Dana-Farber and Children's Hospital Boston was ranked as the #2 pediatric cancer hospital in the United States in its 2011-12 Best Children's Hospitals guide. This combined ranking reflects the clinical and scientific strength and depth of the Dana-Farber/Children's Hospital Cancer Center, a partnership of more than 60 years that provides comprehensive care to children with cancer and survivors of pediatric cancers.

Program Success Monitored By  We set standards for our own practices and measure ourselves against other comprehensive cancer centers nationwide. We measure five different aspects of patient care: effectiveness, patient and family satisfaction, safety, equitable access, and timeliness. In addition, U.S. News & World Report publishes its Best Hospitals guide each year as a reference for patients who are reviewing their medical care options. The overall score is based on professional reputation, mortality rates, patient safety, and a grouping of care-related factors such as nursing and patient services.
Examples of Program Success 

At Griffin’s 8-week checkup, his pediatrician found that his belly was abnormally large and sent him to Children’s Hospital. After the test results came in, pediatric oncologist Dr. Lindsay Frazier met with the family to explain Griffin's cancer. This was a hard conversation for Griffin's parents, but Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) "had a psychologist available to speak with us, which helped emotionally," says Griffin’s mother, Melissa. "And Dr. Frazier even called us at home the following Saturday to ask how we were managing."

Griffin's cancer was called neuroblastoma and his care was transferred to two specialists at DF/CHCC. By the time he was 10 months old, Griffin had beaten cancer.

Looking back, Melissa feels lucky to live so close to Dana-Farber. "I know it sounds odd, but I looked forward to going to the Jimmy Fund Clinic because we genuinely felt that everyone there cared about us. It was a good place for us during that period of our lives."

B. Research

Research, both basic and clinical, remains at the core of our mission. Our researchers are currently trailblazing the concept of personalized medicine, tailoring therapies to each patient, to develop less invasive and toxic treatments.
Budget  n/a
Category  Medical Research, General/Other Cancer Research
Population Served Adults Children and Youth (0 - 19 years)
Program Short-Term Success  In 2011, the Dana-Farber/Brigham and Women’s Cancer Center boldly and successfully launched Profile, one of the most comprehensive cancer research studies to help accelerate the development of personalized treatments for every person with cancer to be undertaken nationally. This major research study tests all consenting adult patients’ tumor tissue for nearly 500 genetic cancer-causing mutations in 41 cancer genes, using OncoMap technology, a novel screening approach discovered at Dana-Farber. The study will provide researchers with one of the world’s largest databases of cancer genetic abnormalities. Over time, this growing body of information will help scientists discover more about the genetic causes of cancers and increase the development of new, targeted therapies to treat them.
Program Long-Term Success  Dana-Farber is committed to translating basic research findings into clinical applications to ultimately improve treatments and outcomes for patients with all types of cancer. We seek to better understand drug resistance and disease relapse and overcome them through the continued development of targeted and effective “smart” drugs, which attack cancer cells but not normal ones. For example, in 2008, Dana-Farber scientists achieved a medical first by using a targeted drug to drive a patient's metastatic melanoma into remission. When lab tests showed the patient's tumor cells harbored a certain mutated gene, doctors treated her with a drug that blocks the gene's action, resulting in a dramatic reduction in tumor size and activity. In 2011, we received FDA approval for the first drug approved for advanced melanoma in more than 10 years. Over the next decade, the continued translation of our basic discoveries into informed drug development for more effective therapies is a top priority.
Program Success Monitored By  The Office of Research Support Services provides financial and administrative oversight for research at Dana-Farber. The Clinical Trials Office (CTO) develops policies, procedures, and best practices related to clinical trials; coordinates submission and compliance of protocols; assists in the pre-review of protocols before submission for approval; provides guidance related to the operational conduct of a trial, regulatory matters, and multi-center site issues; and facilitates clinical research center (CRC) recruitment, on-boarding and training and  oversight and management of CRC teams. The goal of the CTO is to help assure that a clinical trial protocol is well written, able to be conducted at Dana-Farber and will meet the requirements for scientific review and Institutional Review Board.
Examples of Program Success  Dana-Farber's George Demetri, MD, designed and led an international Phase 3 clinical trial of regorafenib, a new targeted drug that can significantly control life-threatening metastatic disease in patients with gastrointestinal stromal tumors (GIST) that have developed resistance to Gleevec and Sutent, the only two FDA-approved drugs available for this disease. The trial determined that treatment with regorafenib reduces the risk of disease progression or death by more than 70 percent in these patients. In another trial, the novel compound selumetinib has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, non-small cell lung cancer. This study confirmed that chemotherapy and selumetinib might be an effective treatment for KRAS-mutant lung cancer and have implications for the treatment of all cancers that harbor KRAS mutations, including pancreatic and colorectal cancer.

C. Training

A teaching affiliate of Harvard Medical School, DFCI supports participation by its professional staff in medical education, clinical training, and pre-doctoral and post-doctoral research training.
Budget  n/a
Category  Medical Research, General/Other Cancer Research
Population Served Adults Children and Youth (0 - 19 years)
Program Short-Term Success  Dana-Farber is keenly aware that future advances in cancer medicine lie in the imaginations of the talented physicians and scientists poised to be the leaders of tomorrow. The Postdoctoral and Graduate Student Affairs Office supports trainees’ professional development through programs on manuscript writing, grant writing, and laboratory management. Dana-Farber attracts the finest researchers and clinicians in the world, and its junior faculty members benefit from extensive professional development opportunities. All members of the Institute's professional staff hold faculty appointments at Harvard University, and many participate as mentors for institutional graduate and postdoctoral training programs. It is a source of great pride that so many of Dana-Farber’s former trainees are now principal investigators and institutional leaders here and at cancer centers around the world.
Program Long-Term Success  Dana-Farber faculty are consistently recognized for their excellence in medical education, research and clinical training. The Institute offers formal opportunities for career development and implements diversity initiatives to increase the quality and balance of the professional lives of our young faculty. Examples of these innovative programs include the Office for Faculty Development, the Office of Diversity and Talent Management, both of which offer unique teaching and mentoring programs, and access to multiple multi-institutional programs such as those offered through Harvard Catalyst and Dana-Farber/Harvard Cancer Center. Contributing to our efforts to increase the pipeline of future cancer researchers, the Institute also supports instructional programs with high schools, colleges, and community groups that enable underserved students to work in Dana-Farber laboratories and begin their careers in science.
Program Success Monitored By  Biannually, Dana-Farber’s faculty and staff complete an opinion survey as part of efforts to create an ideal work environment. The survey consists of nearly 50 questions (some open-ended) on core values, work environment, organizational performance, diversity and inclusion, pay and benefits and supervisor/staff relationships. The purpose of the survey is to define levels of staff satisfaction/engagement, determine strengths and areas of opportunity, promote honest feedback, gauge if past actions/improvements have been successful and use the results to plan for future improvements. Results from the 2011 survey revealed that Dana-Farber scored 4.23 out of 5 for workplace satisfaction/commitment, outperforming national academic health care average and ranking in the 87th percentile of large academic medical health care organizations. High marks were received in quality care/service to patients, connection to the mission and values, and sense of pride in working for Dana-Farber.
Examples of Program Success  The Pediatric Hematology/Oncology Fellowship Program at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) is one of the most recognized in the nation and has trained more leaders in the hematology and oncology field than any other. The program admits six new fellows per year who spend one year in full-time clinical work and two or more years in research training, depending on previous training and interests. The program is geared to broadly train MD or MD/PhD fellows in areas of clinical research, including outcomes, ethics, epidemiology, therapeutic trials and translational research, or in one of the major basic science disciplines: protein chemistry, structural biology, molecular biology, stem cell and developmental biology, genetics, genomics, immunology, systems biology, neuroscience or cell biology.

D. Community Based Programs

Dana-Farber promotes health in the Greater Boston community through its Community Benefits Program, which brings cancer education & resources to at-risk populations, and through its Center for Community-Based Research, which conducts research to reduce disparities in cancer care. 

Budget  n/a
Category  Health Care, General/Other Public Health
Population Served At-Risk Populations Adults Children and Youth (0 - 19 years)
Program Short-Term Success 

Dana-Farber’s Community Benefits Program aims to make Dana-Farber's care and research findings more accessible to everyone, including our neighbors in local communities. The Institute is committed to bringing cancer prevention and education initiatives to an increasing number of members of the Greater Boston community. Dana-Farber physicians are also committed to educating the public about cancer risk reduction, screening and early detection, and treatment options and survivorship. They reach out to Greater Boston communities to heighten awareness and answer questions through: ongoing presentations at partnering high schools; educational sessions to physicians and patients at community health centers; working with faith-based organizations and in collaboration with the Boston Ministerial Alliance; and speaking engagements to the elderly at low-income housing sites.

Program Long-Term Success  The Institute’s community benefits mission is threefold: to establish quantifiable and sustainable cancer prevention programs focusing on at-risk and underserved populations; provide expertise in cancer care to city and state health departments, community-based agencies and health care providers; and increase accrual of minorities into clinical trials. In addition to bringing cancer prevention, education and resources directly to diverse, at-risk, underserved populations, the Institute also conducts a broad scope of research to identify new interventions that reduce health disparities and improve access to care.
Program Success Monitored By 

To ensure that Dana-Farber’s community outreach activities and programs are meeting the health needs in the community, Dana-Farber’s Community Benefits Office partnered with Health Resources in Action (HRiA), a non-profit public health consultancy organization in Boston, to undertake a comprehensive community health assessment. In Phase I, social, economic, and epidemiological data at the community level were reviewed and analyzed to provide a health portrait of Dana-Farber’s priority communities (Roxbury, Mission Hill, Dorchester, Mattapan, and Jamaica Plain). Phase II involved a comprehensive qualitative study, where Dana-Farber staff, community leaders, and residents provided feedback in focus groups and interviews to identify community needs and assets as well as areas for further community engagement and program expansion. The needs assessment final report was completed in early 2012.

Examples of Program Success  Dana-Farber's Mammography Van is the only mobile mammography program in the Commonwealth of Massachusetts. It provides screening mammograms and breast health education to women age 40 and older.In partnership with community-based organizations and neighborhood health centers, the Van serves all Boston neighborhoods and some surrounding towns. Skilled, board-certified mammography technologists from Dana-Farber perform the exams and films are interpreted by board-certified radiologists. By bringing Dana-Farber's high-quality services directly to the neighborhoods in which women live and work, the Van breaks down cultural, linguistic, financial, and logistical barriers to care and makes mammograms more accessible to women who might otherwise not have access to screening. Likewise, the Patient Navigator Program helps to remove barriers to cancer care for diverse women with low socio-economic status, limited English proficiency, disabilities, or lack of insurance.

CEO/Executive Director/Board Comments

--

Management


CEO/Executive Director Dr. Edward J. Benz, Jr.
CEO Term Start Jan 2000
CEO Email [email protected]
CEO Experience Edward J. Benz, Jr., MD, became the president and chief executive officer of Dana-Farber in 2000 and also serves as chief executive officer of Dana-Farber/Partners Cancer Care, director of Dana-Farber/Harvard Cancer Center, and as a trustee of Dana-Farber/Children's Hospital Cancer Care. Dr. Benz is presently the Richard and Susan Smith Professor of Medicine, professor of Pediatrics, professor of Pathology, and faculty dean for Oncology at Harvard Medical School. He received a bachelor's degree, cum laude, from Princeton University; a medical degree, magna cum laude, from Harvard Medical School; and a master's degree (privatum) from Yale University. Immediately prior to assuming the presidency of the Institute, Dr. Benz was chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine. Author of more than 200 articles, books, chapters, reviews, and abstracts, he is a past president of both the American Society of Hematology and the American Society of Clinical Investigation, and is currently an associate editor of the New England Journal of Medicine.
Co-CEO --
Co-CEO Term Start --
Co-CEO Email --
Co-CEO Experience --

Former CEOs and Terms

Name Start End
-- -- --

Senior Staff

Name Title Experience/Biography
Karen Bird Chief Financial Officer and Assistant Treasurer Karen Bird joined Dana-Farber in 1999 and became chief financial officer and assistant treasurer in 2012. She had previously served as senior vice president for Finance since 2007. Prior to coming to Dana-Farber, Ms. Bird held positions at Faulkner Hospital, where she served as vice president for Network Development, and at New England Medical Center, where she was vice president of Finance. She received a bachelor's degree from Trinity College and a graduate degree from the Harvard School of Public Health.
Susan D. Block MD Chair, Department of Psychosocial Oncology and Palliative Care

Susan D. Block, MD is the Chair of the Department of Psychosocial Oncology and Palliative Care at Dana-Farber and Brigham and Women's Hospital and Co-Director of the Harvard Medical School Center for Palliative Care, a national center of excellence in palliative care education. Dr. Block received her AB from Stanford University, her MD from Case Western Reserve University School of Medicine, and completed residencies in both internal medicine and psychiatry at Beth Israel Hospital in Boston. She is board-certified in both fields and in palliative medicine.

Richard S. Boskey Senior Vice President and General Counsel Richard S. Boskey joined the Institute in 1999. He serves as assistant secretary of Dana-Farber Cancer Institute and Dana-Farber/Partners CancerCare, and secretary of the Dana-Farber Trust, Inc. and Dana-Farber/Children's Hospital Cancer Care. Previously, he served in various positions at Partners HealthCare and Massachusetts General Hospital, including deputy general counsel, and was an associate at the law firm Hill & Barlow. Mr. Boskey received his bachelor's degree from Brown University and his master's and law degrees from the University of Virginia.
Craig A. Bunnell MD, MPH, MBA Chief Medical Officer Craig A. Bunnell, MD, MPH, MBA became the Chief Medical Officer and Medical Director for Adult Ambulatory Oncology in 2012. Dr. Bunnell received his bachelor's degree, summa cum laude, from Colorado College after which he was a Thomas J. Watson Fellow in Stockholm, Sweden. He earned his medical degree from Harvard Medical School and his MPH from the Harvard School of Public Health. He also earned his MBA from the Sloan School of Management at the Massachusetts Institute of Technology. Dr. Bunnell completed his internship, residency and fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as Chief Medical Resident. Dr. Bunnell is a medical oncologist involved in research and the care of patients with breast cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
Beverly R. Ginsburg Cooper MBA Senior Vice President for Research

Beverly R. Ginsburg Cooper came to Dana-Farber in November 2006 from the University of Pennsylvania, where she served for 16 years as executive director of the Abramson Cancer Center. Prior to that, Ms. Ginsburg Cooper was president of Medical Partnerships, Inc., vice president of Pennsylvania Hospital, and chief operating officer of a community hospital.

Ms. Ginsburg Cooper received her bachelor's degree in education from Adelphi University and her MBA from the Wharton School of the University of Pennsylvania. Currently, she is president of the Cancer Center Administrators Forum and a member of the external advisory boards of several comprehensive cancer centers.
James D. Griffin MD Chair, Department of Medical Oncology

James D. Griffin received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he currently is director of the Leukemia Program and chair of the Department of Medical Oncology.

From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.
Anne Gross RN, PhD Vice President Adult Ambulatory Nursing and Clinical Services Anne Gross, RN, PhD, serves as Vice President Adult Ambulatory Nursing and Clinical Services at Longwood and Faulkner.   In this capacity Anne is accountable for all nursing practice and non-physician clinical services at Longwood and Faulkner. Anne has a bachelor's from Maryville College and St. Louis University, master's of science from Boston College, and in 2010, Dr. Gross received her PhD in nursing from The University of Massachusetts Boston.
Jay R. Harris MD Chair, Department of Radiation Oncology Jay R. Harris, MD received his medical degree from Stanford University in 1970. He trained in radiation oncology at the Harvard Joint Center for Radiation Therapy, and joined the Dana-Farber staff in 1977. Dr. Harris chairs the Department of Radiation Oncology at Dana-Farber, Brigham and Women's Hospital, and Boston Children's Hospital, which constitute the Longwood Radiation Oncology Center. He is also a professor of Radiation Oncology at Harvard Medical School.
Deborah Hicks Senior Vice President for Human Resources

Deborah Hicks joined Dana-Farber as the Senior Vice President for Human Resources in 2011. Prior to joining Dana-Farber, Hicks served as the associate dean and chief human resources officer at Harvard Medical School.

She joined Harvard Medical School in January 2009. Previously, Hicks was the vice president of Human Resources at Harvard Pilgrim Health Care (HPHC), joining HPHC in 1988 and becoming vice president of Human Resources and part of the leadership team in 1999, where she was instrumental in supporting the organization during the turnaround of HPHC from receivership to profitability.
 
She currently serves as chair of the Board of the New England Human Resources Association, holds a master's degree in Counseling Psychology/Organizational Management from Antioch University, and a bachelor's degree from the University of Massachusetts at Amherst.
Joseph Jacobson MD Chief Quality Officer

Joseph Jacobson, MD, joined Dana-Farber Cancer Institute in 2011 as the Institute's first Chief Quality Officer, overseeing clinical quality programs across Dana-Farber and its affiliates, and representing Dana-Farber in regional and national quality improvement efforts. He focuses on clinical process measurement and improvement, efficiency and effectiveness of care, and quality leadership development. He is also a member of and practicing physician in our Thoracic Oncology Program.

Before joining Dana-Farber, Dr. Jacobson served as the Chairman of Medicine at North Shore Medical Center. As part of the Partners HealthCare system, he co-developed and currently co-directs the Partners Clinical Process Improvement Leadership Program. He has an extensive track record in quality measurement and quality improvement, serving as a founding member of the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative, as co-developer of the ASCO/ONS Chemotherapy Safety Standards and as recent past Chair of the ASCO Quality of Care Committee.

Philip Kantoff MD Chief Clinical Research Officer

Philip Kantoff, MD graduated from Brown University Medical School in 1979. After completing his internship, residency and chief residency in internal medicine at New York University Hospital and Bellevue Hospital, he spent four years at the National Institutes of Health conducting research in gene therapy. He joined Dana-Farber in 1987 and became director of what is now the Lank Center for Genitourinary Oncology in 1988.

Dr. Kantoff is chief of the Division of Solid Tumor Oncology, leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program, and director of the Prostate Cancer Specialized Program of Research Excellence (SPORE). He is also a professor of Medicine at Harvard Medical School. He became chief clinical research officer in October 2006.

Elizabeth Liebow MS Vice President for Clinical Planning and Network Operations In 2012, Elizabeth Liebow, MS assumed responsibilities as the Vice President for Clinical Planning and Network Operations. Elizabeth's department supports key interdisciplinary clinical planning projects and oversee the development of the Institute's growing network of satellite clinics and management contracts. Prior to joining Dana-Farber in 2004, Elizabeth Liebow served as director of business development at Partners HealthCare from 1997 to 2004 and administrative director of pediatrics at Boston Medical Center from 1994 to 1997. She has a bachelor's in economics from Brandeis University and a masters of science in health policy and management from Harvard School of Public Health.
Lee M. Nadler MD Senior Vice President, Experimental Medicine Lee M. Nadler, MD received his medical degree from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor immunology, he completed a medical oncology fellowship at Dana-Farber, where he joined the staff in 1980. During his tenure at Dana-Farber, he has served as chief of the Division of Hematologic Malignancies and was the first chair of the Department of Adult Oncology. Dr. Nadler is the Virginia and D.K. Ludwig Professor of Medicine at Harvard Medical School and the Pan Mass Challenge Senior Investigator at Dana-Farber.
Stuart H. Orkin MD Chairman, Department of Pediatric Oncology Stuart H. Orkin, MD received his medical degree in 1972 from Harvard Medical School, followed by postdoctoral research at the National Institutes of Health and clinical training in pediatrics and hematology-oncology at Children's Hospital Boston and Dana-Farber, where he joined the faculty in 1978. Dr. Orkin is a Howard Hughes Medical Institute Investigator and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Over the past decade, his laboratory has defined critical nuclear regulators of hematopoiesis. 
Maria Papola Senior Vice President for Institute Operations

Maria Papola joined Dana-Farber Cancer Institute as the Vice President for Facilities Management and Real Estate in 2008 and was named Senior Vice President for Institute Operations in 2012.

Before joining Dana-Farber, Ms. Papola served as Vice President for Corporate Real Estate Services at Saint Vincent Catholic Medical Centers of New York. Prior to Saint Vincent's, Ms. Papola held various management roles at Memorial Sloan-Kettering Cancer Center after completing her administrative residency there.

Ms. Papola holds a masters in health administration from Cornell University and a bachelors degree in physical anthropology from Rutgers University. She is a longtime member of several alumni boards at Cornell where she serves as adjunct lecturer on facilities planning.

Susan S. Paresky Senior Vice President for Development Susan S. Paresky joined the Institute in 1997. She was associate dean for Development at the Harvard School of Public Health, where she executed the school's fundraising program as part of Harvard University's $2 billion campaign. She has also held senior positions at Brandeis University and Wheaton College. Ms. Paresky received her business degree from Simmons Graduate School of Management and her bachelor's degree from Wheaton College, where she now serves as a trustee.
Dorothy E. Puhy Executive Vice President and Chief Operating Officer

Dorothy E. Puhy became the Institute's chief operating officer in 2012. She previously served as chief financial officer and director for Fiscal Services since 1994, and executive vice president since 2004. Ms. Puhy is chief administrative officer of Dana-Farber/Partners CancerCare and treasurer of HealthCare Dimensions, Inc.

Prior to joining Dana-Farber, she was chief financial officer at New England Medical Center in Boston and a senior manager at Ernst and Whinney. Ms. Puhy received her bachelor's degree from the University of Pennsylvania and her business degree from its Wharton School.

David Read MBA, MPH Vice President for Ambulatory Care Operations, Ambulatory Oncology, Longwood, and Ambulatory Care at the Yawkey Center In 2012, David Read, MBA, MPH, assumed the role of Vice President for Ambulatory Care Operations, Adult Ambulatory Oncology, Longwood, and oversees all administrative functions that support ambulatory care delivery at the Yawkey Center. David supports, design and lead implementation of initiatives that create a high-performing and efficient ambulatory care environment to support clinicians in their daily care delivery. He will also lead implementation of Dana-Farber’s patient access program for the Longwood practice. David continues to serve the Department of Medical Oncology as Department Administrator, overseeing administration of its clinical and research functions.
Patricia Reid Ponte RN, DNSc, FAAN Senior Vice President for Patient Care Services and Chief Nursing Officer Patricia Reid Ponte, RN, DNSc, FAAN, also serves as the nursing director of the Hematology/Oncology, Bone Marrow Transplant Program at Brigham and Women's Hospital and as the cancer center nurse leader for Dana-Farber/Partners CancerCare. She received her bachelor's degree in nursing from the University of Massachusetts, Amherst, and her master's and doctorate degrees from Boston University. Dr Reid Ponte completed a three year Robert Wood Johnson Nurse Executive Fellowship in 2004 and was inducted into the American Academy of Nursing.
Barrett J. Rollins MD, PhD Chief Scientific Officer Barrett J. Rollins, MD, PhD received his doctoral degree in 1979 and medical degree in 1980 from Case Western Reserve University and completed his internship and residency in internal medicine at Beth Israel Hospital, Boston. He then performed clinical and research fellowships in medical oncology at Dana-Farber and joined the Institute's faculty in 1986. Dr. Rollins is currently Professor of Medicine at Harvard Medical School.
Stephen E. Sallan MD Chief of Staff Emeritus Stephen E. Sallan, MD joined the institute in 1973 as a trainee before becoming a member of the staff in the Department of Pediatric Oncology. He was named chief of staff and chairman of the Medial Staff Executive Committee in 1995. Dr. Sallan received his undergraduate and medical degrees from Wayne State University. He is presently a professor of Pediatrics at Harvard Medical School, and was named the Quick Family Senior Investigator in 2002.  In 2012, Dr. Sallan was named Chief of Staff Emeritus.
Lawrence N. Shulman MD Chief of Staff, Senior Vice President for Medical Affairs, Director of Regional Strategy Development and Director of the Center for Global Cancer Medicine Lawrence N. Shulman, MD became chief of staff in 2012, at which time he also accepted leadership roles as the Institute’s director of regional strategy development and director of the Center for Global Cancer medicine. Prior to these positions, Dr. Schulman had served as chief medical officer and senior vice president for Medical Affairs at the Institute since 2002. Prior to that, he served as Dana-Farber's vice chair for Clinical Services for the Department of Adult Oncology. Dr. Shulman is involved in clinical research and care for patients with breast cancer and lymphoma. He is an associate professor of Medicine at Harvard Medical School, and received his bachelor's degree from Syracuse University and his medical degree from Harvard Medical School.
Steven R. Singer Senior Vice President for Communications Steven R. Singer joined the Institute in 1997. He previously served as director of Communications and Public Affairs and adjunct lecturer at Harvard University's John F. Kennedy School of Government. He has worked as a press secretary in the U.S. House of Representatives, and is past chair of the National Cancer Institute's Public Affairs Network. Mr. Singer received his bachelor's degree from Colby College and a master's degree in public administration from Harvard University's Kennedy School.
Scott J. Swanson MD Chief Surgical Officer Scott J. Swanson, MD joined Dana-Farber as Chief Surgical Officer in 2008. He is the Disease Center Leader of the Thoracic Oncology Program, and leads a multidisciplinary group focused on optimizing the experience and outcome for patients with thoracic malignancy. Dr. Swanson is also director of the Minimally Invasive Thoracic Surgery Program at Brigham and Women’s Hospital, and Professor of Surgery at Harvard Medical School. He received a bachelor’s degree, magna cum laude, from Amherst College, and a medical degree from Harvard Medical School. 
Annick Van den Abbeele MD Chief, Department of Imaging Annick Van den Abbeele, MD received her BA and MD from the Université Catholique de Louvain in Belgium. Following a residency in Pediatrics at the Université Catholique de Louvain and a Neonatology fellowship at Vanderbilt University Medical Center in Nashville, TN, she completed a residency in Nuclear Medicine and a fellowship in Radiology at Brigham and Women's Hospital, Boston, MA and Harvard Medical School, followed by seven years in basic sciences research. In 1994, Dr. Van den Abbeele assumed the position of Director of Nuclear Medicine at the Dana-Farber Cancer Institute, and in 2004 became the Clinical Director of Radiology. In 2006, she was promoted to Chief of the Department of Imaging. She has been a faculty member at Harvard Medical School since 1987.

Awards

Award Awarding Organization Year
-- -- --

Affiliations

Affiliation Year
-- --
Member of state association of nonprofits? No
Name of state association --

External Assessments and Accreditations

External Assessment or Accreditation Year
-- --

Collaborations

--

CEO/Executive Director/Board Comments

--

Foundation Comments

--

Staff Information

Number of Full Time Staff 3,329
Number of Part Time Staff 794
Number of Volunteers 64
Number of Contract Staff 0
Staff Retention Rate % 81%

Staff Demographics

Ethnicity African American/Black: 365
Asian American/Pacific Islander: 749
Caucasian: 2,671
Hispanic/Latino: 224
Native American/American Indian: 1
Other: 113
Other (if specified): multi-race and unspecified
Gender Female: 3,329
Male: 794
Not Specified 0

Plans & Policies

Organization has Fundraising Plan? Under Development
Organization has Strategic Plan? No
Years Strategic Plan Considers --
Management Succession Plan --
Business Continuity of Operations Plan --
Organization Policies And Procedures Under Development
Nondiscrimination Policy Under Development
Whistle Blower Policy No
Document Destruction Policy No
Directors and Officers Insurance Policy --
State Charitable Solicitations Permit --
State Registration --

Risk Management Provisions

--

Reporting and Evaluations

Management Reports to Board? Yes
CEO Formal Evaluation and Frequency Yes Annually
Senior Management Formal Evaluation and Frequency Yes Annually
Non Management Formal Evaluation and Frequency Yes Semi-Annually

Governance


Board Chair Mr. Joshua Bekenstein
Board Chair Company Affiliation Bain Capital Partners, LLC
Board Chair Term Jan 2011 -
Board Co-Chair --
Board Co-Chair Company Affiliation --
Board Co-Chair Term -

Board Members

Name Company Affiliations Status
Andrea R. Abraham n/a --
Gerhard R. Andlinger Andlinger & Co. --
Michael Andrews n/a --
David Auerbach n/a --
Delores Barr Weaver n/a --
David Barrett Polaris Venture Partners --
Robert A. Belfer Belfer Management LLC --
Dr. Edward J. Benz Jr. Dana-Farber Cancer Institute --
Roger Berkowitz Legal Sea Foods --
Armin G. Biller n/a --
Jack Blais BlaisCo, LLC --
Betty Ann Blum n/a --
Justice Stephen G. Breyer Supreme Court of The United States --
Honorary Frederick L. Brown Massachusetts Appeals Court --
Dr. Craig Bunnell Dana-Farber Cancer Institute --
J. Gary Burkhead n/a --
Kennett F. Burnes Esq. n/a --
Stephen J. Burton CBS4 --
Richard A. Cantor Cantor Foundation --
Michael A. Champa n/a --
George A. Cloutier American Management Services --
Marc A. Cohen OPNET Technologies --
Joseph F. Cotter n/a --
Gary L. Countryman Liberty Mutual Insurance Companies --
Howard Cox Greylock --
Neal J. Curtin Esq. Bingham McCutchen, LLP --
Alice Cutler n/a --
Charles A. Dana III Newport Shipyard Corporation --
Lee S. Daniels n/a --
Nader F. Darehshori n/a --
Peter de Roetth Account Management, LLC --
David A. Dechman Summit Rock Advisors --
Emily F. DiMaggio n/a --
Jim Donovan Goldman Sachs Corp. --
James M. Dow n/a --
John P. Dunfey New Hampshire Charitable Foundation --
Donald Dwares n/a --
Michael Eisenson Charlesbank Capital Partners, LLC --
Ed Eskandarian Arnold Worldwide Partners --
John S. Farber Old Trail School --
Stephen B. Farber Concordia Group --
Thomas A. Farrington Prostate Health Education Network, Inc. --
James L. Fine Levy & Droney P.C. --
Stephen Fine The Biltrite Corporation --
Deborah First Deborah First Communications --
Robert First n/a --
Charles Forman n/a --
Dr. Emil Frei III n/a --
Michael Frieze Gordon Brothers Group --
Dozier Gardner Fernwood Advisors --
Dr. Arthur Gelb Four Sigma Corporation --
Nancy Gibson n/a --
William M. Gillen Eaton Vance Investment Counsel --
Michael Gordon Vinik Asset Management --
Abraham D. Gosman n/a --
Dr. James D. Griffin Dana-Farber Cancer Institute --
Richard L. Grubman Highfields Capital Management --
Judy Hale Granite Telecommunications LLC --
David Harkins Thomas H. Lee Partners, LP --
Marian L. Heard n/a --
Frances Heller n/a --
Alan Hirschfield Norman Hirschfield & Co. --
Thomas F. Holt Jr., Esq. K&L Gates --
Barbara H. Hugus PhD n/a --
Jane P. Jamieson n/a --
Glenn M. Johnson Northland Investment Corporation --
Scott L. Kafker Massachusetts Appeals Court --
William Karol Koda Enterprises Group, LLC --
Stephen B. Kay Goldman, Sachs, & Company --
Patricia D. Kelsey n/a --
Michelle Kessler n/a --
Michael J. Kittredge n/a --
Brian J. Knez Castanea Partners --
Ruth Kopelman n/a --
Steven P. Koppel n/a --
Paul B. Kopperl n/a --
Stephen P. Koster Esq. Vacovec, Mayotte & Singer, LLP --
Daniel Kraft International Forest Products --
Robert K. Kraft The Kraft Group --
Sandra G. Krakoff n/a --
Phyllis Krock n/a --
Althea Lank n/a --
Rebecca Latimore IBM Institute For Business Value --
Jonathan S. Lavine Bain Capital Partners, LLC --
Kenneth H.M. Leet Granite Ridge LLP --
John Legere n/a --
Kenneth R. Levine Seaview Consulting, Inc. --
Roger A. Lockwood Lockwood/McKinnon Group --
Richard K. Lubin Berkshire Partners, LLC --
Bradley Lucas Anton Lucas, Inc. --
Larry Lucchino Boston Red Sox --
Hildegarde E. Mahoney Harvard Mahoney Neuroscience Inst. --
Peter Maich n/a --
Roger M. Marino Marino Capital Corp --
John L. Marshall III Marshall Properties, Inc. --
Thomas J. May NSTAR --
William F. McCall Jr. McCall & Almy Inc. --
Joseph C. McNay Essex Investment Mgmt. Co., Inc. --
William F. Meagher Jr. n/a --
David S. Moross Falconhead Capital --
Richard P. Morse n/a --
Dr. David G. Nathan Dana-Farber Cancer Institute --
George A. Neale Liberty Mutual Insurance Companies --
Charlie Nirenberg First Merchants Group --
Joseph E. Norberg n/a --
Brian O'Connor Miles Logue Financial Group --
John J. O'Connor n/a --
Vincent M. O'Reilly Boston College --
Dr. Stuart H. Orkin Dana-Farber Cancer Institute --
Edward O. Owens Owens Companies, Inc. --
Peter Palandjian Intercontinental Real Estate Corp. --
Dr. Arthur M. Pappas UMass Medical School --
Ted Pasquarello Paris Trust LLC --
Jean F. Pearlstein n/a --
David B. Perini n/a --
Eileen Perini n/a --
Jennifer Perini Everyman Pictures --
Steven P. Perlmutter Esq. Robinson & Cole --
Susan M. Poduska Poduska Family Foundation --
Betsy Pohl MFS Investment Management --
Alison Poorvu Jaffe n/a --
William J. Poutsiaka Chartis Insurance --
John M. Randolph n/a --
Dr. Kathleen M. Randolph n/a --
Jim Rappaport New Boston Fund, Inc. --
John P. Reardon Jr. Harvard --
Shari E. Redstone National Amusements, Inc. --
Sumner M. Redstone National Amusements, Inc. --
Amy Reiner n/a --
Robert L. Reynolds Putnam Investments --
Dr. Barrett J. Rollins Dana-Farber Cancer Institute --
Ann M. Rosenberg D'Vine Wine --
Harvey Rosenthal n/a --
Edward F. Rover Charles A. Dana Foundation --
Robert J. Sachs Esq. Continental Consulting Group, LLC --
James Sadowksy Williams Distributing Corporation --
Barbara Sadowsky n/a --
Dr. Stephen E. Sallan Dana-Farber Cancer Institute --
Marjorie Salmon Assoc. Counselors and Psychotherapists --
Malcolm S. Salter Harvard Business School --
H. Terrence Samway n/a --
Rebecca L. Sanders Destin Realty, Inc. --
Judith P. Schlager The Bullfinch Companies, Inc. --
Richard N. Seaman Seaman Corporation --
Thomas P. Sellers n/a --
Laura Jeanne Sen BJ's Wholesale Club Incorporated --
Paul Severino n/a --
Jean S. Sharf Sharf Marketing Group, Inc. --
Paula L. Sidman The Beacon Companies --
Richard A. Smith Smith Management Company --
Susan F. Smith n/a --
Amy Smith Berylson Chestnut Hill Ventures --
Ruth F. Snider n/a --
Jerry Socol The Socol Group --
Gloria H. Spivak n/a --
Robert Stansky Fidelity Investments --
William Starr Pan Mass Challenge --
James Stoneman Seljim Investments --
Patrick J. Sullivan Game Creek Video LLC --
Fifi Swerling Kellem Dana-Farber Cancer Institute --
Jean C. Tempel First Light Capital --
Beth F. Terrana n/a --
David Ting Mugar Enterprises, Inc. --
J. Wayne Weaver n/a --
Karen L. Webster Market Platform Dynamics --
Laura Weissman Davis n/a --
T. Conrad Wetterau Quality Beverage Co. --
Gregory A. White Thomas H. Lee Partners, LP --
Frederica M. Williams Whittier Street Health Center --
Winnie Wong n/a --
Carl Yastrzemski Eaton Vance Investment Counsel --
Jay Yost Fidelity Investments --
Mortimer B. Zuckerman Boston Properties --

Constituent Board Members

Name Company Affiliations Status
-- -- --

Youth Board Members

Name Company Affiliations Status
-- -- --

Advisory Board Members

Name Company Affiliations Status
-- -- --

Board Demographics

Ethnicity African American/Black: 11
Asian American/Pacific Islander: 2
Caucasian: 141
Hispanic/Latino: 0
Native American/American Indian: 0
Other: 0
Other (if specified): 1 Middle Eastern
Gender Female: 42
Male: 113
Not Specified 0

Board Information

Board Term Lengths 0
Board Term Limits 0
Board Meeting Attendance % 75%
Written Board Selection Criteria No
Written Conflict Of Interest Policy Under Development
Percentage of Monetary Contributions 100%
Percentage of In-Kind Contributions --
Constituency Includes Client Representation Yes

Standing Committees

  • Audit
  • Campus Planning and Development
  • Communications / Promotion / Publicity / Public Relations
  • Community Outreach / Community Relations
  • Compensation
  • Development / Fund Development / Fund Raising / Grant Writing / Major Gifts
  • Executive
  • Finance
  • Investment
  • Personnel
  • Scientific Advisory

CEO/Executive Director/Board Comments

Please Note: We do not disclose the percentage of board members making monetary contributions; the value is not 0%.

Foundation Comments

--

Financials


Revenue vs. Expense ($000s)

Expense Breakdown 2013 (%)

Expense Breakdown 2012 (%)

Expense Breakdown 2011 (%)

Prior Three Years Total Revenue and Expense Totals

Fiscal Year 2013 2012 2011
Total Revenue $1,056,841,650 $1,021,271,591 $1,002,464,148
Total Expenses $1,023,723,858 $982,077,009 $965,097,718

Prior Three Years Revenue Sources

Fiscal Year 2013 2012 2011
Foundation and
Corporation Contributions
-- -- --
Government Contributions $132,889,339 $143,574,943 $164,905,675
    Federal -- -- --
    State -- -- --
    Local -- -- --
    Unspecified $132,889,339 $143,574,943 $164,905,675
Individual Contributions $239,084,267 $235,972,261 $255,325,600
Indirect Public Support $466,445 $370,559 $370,150
Earned Revenue $643,884,073 $607,158,776 $545,363,835
Investment Income, Net of Losses $224,324 $293,433 $332,089
Membership Dues -- -- --
Special Events $19,079,607 $17,018,157 $18,215,647
Revenue In-Kind -- -- --
Other $21,213,595 $16,883,462 $17,951,152

Prior Three Years Expense Allocations

Fiscal Year 2013 2012 2011
Program Expense $836,192,565 $831,685,201 $821,087,868
Administration Expense $166,191,419 $130,473,286 $127,308,133
Fundraising Expense $21,339,874 $19,918,522 $16,701,717
Payments to Affiliates -- -- --
Total Revenue/Total Expenses 1.03 1.04 1.04
Program Expense/Total Expenses 82% 85% 85%
Fundraising Expense/Contributed Revenue 5% 5% 4%

Prior Three Years Assets and Liabilities

Fiscal Year 2013 2012 2011
Total Assets $1,790,428,000 $1,605,048,000 $1,487,622,000
Current Assets $311,537,000 $248,483,000 $201,452,000
Long-Term Liabilities $414,739,000 $394,630,000 $379,805,000
Current Liabilities $193,306,000 $174,255,000 $166,734,000
Total Net Assets $1,182,383,000 $1,036,163,000 $941,083,000

Prior Three Years Top Three Funding Sources

Fiscal Year 2013 2012 2011
1st (Source and Amount) -- --
-- --
-- --
2nd (Source and Amount) -- --
-- --
-- --
3rd (Source and Amount) -- --
-- --
-- --

Financial Planning

Endowment Value $351,316,236.00
Spending Policy Percentage
Percentage(If selected) 7.0%
Credit Line Yes
Reserve Fund Yes
How many months does reserve cover? --

Capital Campaign

Are you currently in a Capital Campaign? No
Capital Campaign Purpose --
Campaign Goal --
Capital Campaign Dates -
Capital Campaign Raised-to-Date Amount --
Capital Campaign Anticipated in Next 5 Years? Yes

Short Term Solvency

Fiscal Year 2013 2012 2011
Current Ratio: Current Assets/Current Liabilities 1.61 1.43 1.21

Long Term Solvency

Fiscal Year 2013 2012 2011
Long-term Liabilities/Total Assets 23% 25% 26%

CEO/Executive Director/Board Comments

--

Foundation Comments

Financial summary data in the charts and graphs above for the revenue and expenses are per the organization's IRS Form 990s; asset and liability data is per the audited financials.  Contributions from foundations and corporations are listed under individuals when the breakout was not available.

Documents


Other Documents

No Other Documents currently available.

Impact

The Impact tab is a section on the Giving Common added in October 2013; as such the majority of nonprofits have not yet had the chance to complete this voluntary section. The purpose of the Impact section is to ask five deceptively simple questions that require reflection and promote communication about what really matters – results. The goal is to encourage strategic thinking about how a nonprofit will achieve its goals. The following Impact questions are being completed by nonprofits slowly, thoughtfully and at the right time for their respective organizations to ensure the most accurate information possible.


1. What is your organization aiming to accomplish?

--

2. What are your strategies for making this happen?

--

3. What are your organization’s capabilities for doing this?

--

4. How will your organization know if you are making progress?

--

5. What have and haven’t you accomplished so far?

--